secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001193125-24-161601
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma holds 2024 annual meeting; all proposals approved
--------------------------------------------------------------------

- Elected Elizabeth Nabel (147.8M for, 16.2M withheld) and Lynn Seely (150.1M for, 13.9M withheld) as Class III directors.
- Ratified Ernst & Young as auditor for FY2024 with 198.6M votes for, 153.7K against, 57K abstentions.
- Advisory say-on-pay approved: 108.8M for, 47.0M against, 8.2M abstentions; broker non-votes 34.8M.
- Quorum of 77.98% (198.8M shares) represented at the June 14, 2024 virtual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312524161601/0001193125-24-161601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312524161601/d855288d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-161601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer